CASE STUDY

SITE AND PATIENT SOLUTIONS

amrClinical
Patient Centered | Trusted Research

Phase III Hypercholesterolemia Trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABC123 in Adults With Hypercholesterolemia

14%
OF TOTAL STUDY ENROLLMENT

58%
OVER TARGET ENROLLMENT

91%
RETENTION RATE

ALL SITES
ENROLLED

"I greatly appreciate your team's efforts, time spent, proactivity and responsiveness to all deliverables, which allowed you to not only reach Site Ready, but do so 2 days ahead of projected global estimates. This is an amazing accomplishment, which is not typically achieved, and you should be proud."

-Global Study Manager

Study Background

Indication: Adults With Hypercholesterolemia

Timelines:

-Study LSLV (Plan): 11AUG25
-Study LSLV (Scheduled): 30JUL25

*AMR LSLV scheduled 12 days earlier than plan

6
AMR SITES

3
PHASE

65+
YEARS OLD

AMR Clinical Highlights

- All AMR Clinical sites opened early
- AMR Clinical sites randomized 14% of total study subjects with 12% of study sites
- AA and Hispanic population met or exceeded expectations
- Retention rate 91%
- 70% of completed subjects enrolled in open label extension protocol
- Enrollment 58% above target

Strong Contributor to Program-Level Diversity Goals (Race and Gender)